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Introduction
Antiphospholipid antibodies (aPLs) constitute a heterogeneous group of autoantibodies, clinically diagnosed as anti-cardiolipin antibodies (aCLs), anti-b 2 -glycoprotein I (b 2 GPI) antibodies, and/or positivity in the functional lupus anticoagulant (LA) test [1, 2] . aPLs are the immunologic markers of antiphospholipid syndrome (APS), which is clinically characterized by venous, arterial or small-vessel thrombosis and/or pregnancy morbidities. aPLs are overrepresented in systemic lupus erythematosus (SLE) patients, both in cases with clinical APS manifestations and in those without [2, 3] . The most important antigen for aPLs is b 2 GPI, a scavenger molecule, which has a specific binding site for the negatively charged phospholipid phosphatidylserine (PS) [4] . By binding to PS, b 2 GPI facilitates clearance of particles and apoptotic bodies from the circulation [5] . Major sources of PS expression in the circulation are cellderived microparticles (MPs).
MPs are small membrane-surrounded structures that are released during cell activation or apoptosis by a blebbing process [6] . MPs range in size between 0.1 lm and 1.0 lm in diameter, and commonly expose PS, as PS is translocated to the outer leaflet of the plasma membrane of activated or apoptotic cells during MP shedding [7] . Besides expressing PS, they can also contain an ensemble of membrane and intracellular molecules, depending on their cellular origin [8] . We have previously demonstrated that SLE and APS patients have considerably higher numbers of circulating MPs than healthy controls [9, 10] . We and others have also observed that a disproportionally large number of these MPs in both groups of patients do not expose PS [9] [10] [11] . We hypothesized that the lack of PS expression could be explained by autoantibodies, such as anti-b 2 GPI, binding to b 2 GPI-PS complexes found on the MP surfaces [12] . In order to understand these findings, we evaluated the numbers and expression of b 2 GPI on MPs in SLE patients with and without aPLs/anti-b 2 GPI, and compared them with those in healthy controls. In addition, we performed in vitro experiments to evaluate the binding properties of b 2 GPI on MPs, and investigated the presence of immunoglobulins of the IgG type on MPs.
Materials and methods

Study population and blood sampling
From the Karolinska SLE cohort, 40 patients were selected on the basis of anti-b 2 GPI (IgG and IgM) and aCL (IgG and IgM) profile and LA results [13] . SLE patients were aged between 20 years and 80 years, and fulfilled at least four of the 1982 revised classification criteria for SLE according to the American College of Rheumatology [14] . Eighteen patients had aPLs and 22 patients were negative for aPLs ( Table 1) . As a control group, 19 healthy volunteers were included. The local ethics committee at Karolinska University Hospital and Karolinska Institutet approved the study. All study subjects gave written informed consent to participate.
Blood sampling was performed after overnight fasting according to standardized protocols. Blood was drawn into vacutainer tubes containing sodium citrate (0.129 M). Platelet-poor plasma (PPP) was obtained after centrifugation at 2570 9 g for 20 min at room temperature, and frozen within 1 h at À 80°C until analysis.
Laboratory measurements aCLs and anti-b 2 GPI antibodies were analyzed with multiplex immunoassays (BioPlex 2200 APLS IgG and IgM; Bio-Rad Laboratories, Hercules, CA, USA). The multiplex assays were regarded as positive if the level was ≥ 20 U mL À1 . All cut-off levels corresponded to the 99th percentile of healthy blood donors. LA was measured by use of a modified dilute Russell viper venom method (Biopool, Ume a, Sweden) with Bioclot LA, according to the standard procedure.
The plasma levels of b 2 GPI were determined with a commercial ELISA (Antibodies-online, Aachen, Germany), according to the manufacturer's instructions. Intra-assay and inter-assay coefficients of variation are 4.6% and 7.7%, respectively, according to the manufacturer.
Measurement of MPs
PPP was thawed in a water bath for ≈ 5 min (37°C), and then centrifuged at 2000 9 g for 20 min at room temperature. The supernatant was then recentrifuged at 13 000 9 g for 2 min at room temperature. )/standard beads counted (FlowCount; Beckman Coulter). The expression of IgG is shown as mean fluorescence intensity (MFI) of anti-IgG in the mpIC gate. The intra-assay and inter-assay coefficients of variation for MP measurement were < 9%.
Binding of b 2 GPI to MPs
To investigate the binding properties of b 2 GPI on MPs, in vitro experiments were performed. Initially, a high concentration of platelet-derived MPs (PMPs) was generated from fresh platelets obtained from a healthy volunteer. Briefly, the citrated whole blood was centrifuged at 200 9 g for 10 min at room temperature in order to obtain platelet-rich plasma (PRP). The PRP was then carefully collected, and activated with the platelet agonist ADP (35 lM) for 20 min at room temperature. After activation, the PRP was first centrifuged at 2000 9 g for 20 min at room temperature to separate the platelets from the supernatant containing PMPs. Then, the supernatant was centrifuged at 20 800 9 g for 45 min at room temperature twice (phosphate-buffered saline wash in between). The supernatant was removed, and a PMPenriched pellet was obtained.
Prior to the experiment, the sample was labeled with anti-b 2 GPI-PE and lactadherin-FITC in order to measure the baseline values of b 2 GPI and PS expression by flow cytometry, as described above. Then, the sample was aliquoted and incubated with increasing concentrations of b 2 GPI (0-40 lg mL À1 ) for 120 min at 37°C. After the incubation, the samples were again labeled with antib 2 GPI-PE and lactadherin-FITC, and b 2 GPI and PS expression was measured by flow cytometry.
Statistical analysis
Prior to statistical analysis, data were log-transformed, if necessary, to obtain a normal distribution. For group comparisons, ANOVA or Student's t-test was used. A twofactor repeated-measures ANOVA was used in the in vitro experiments, where factor 1 was MP numbers over time and factor 2 was the concentration of b 2 GPI (Fig. 4) . A P-value of < 0.05 was considered to be significant. Statistical analysis was performed with JMP v.12.2 (SAS Institute, Cary, NC, USA).
Results
Basic demographics and the aPL status of patients and controls are shown in Table 1 .
Total numbers of MPs (defined only by forward and side characteristics by flow cytometry, i.e. size and complexity) in SLE patients, both aPL/anti-b 2 GPI-positive and aPLnegative, were significantly higher than in controls (Fig. 1) . The total number of MPs did not differ with aPL status. The highest concentrations of b 2 GPI-positive MPs were observed in healthy controls. aPL/anti-b 2 GPI-positive patients had lower numbers of b 2 GPI-positive MPs than both aPL-negative patients and healthy controls (Fig. 2) . Moreover, we analyzed the presence of immunoglobulins (IgG type) on larger MPs, i.e. mpICs. In this experiment, all SLE patients were combined (n = 40) and compared with healthy controls (n = 19). In the mpIC gate, the MFI of IgG expression was significantly higher in SLE patients than in controls ( Fig. 3 ; P < 0.001). ; P < 0.02). Incubation of PMPs with b 2 GPI significantly increased the concentration of PS-negative PMPs in the sample, whereas the concentration of PS-positive PMPs declined (P < 0.0001; Fig. 4A ). In addition, b 2 GPI preferentially bound to PMPs that were PS-positive rather than PSnegative (P < 0.001; Fig. 4B) .
Discussion
Our results demonstrate that MPs express the scavenging molecule b 2 GPI on their surfaces. Despite having high numbers of total MPs, aPL/anti-b 2 GPI-positive SLE patients had lower concentrations of b 2 GPI-expressing MPs than both aPL-negative SLE patients and healthy controls. These results imply that b 2 GPI, which has previously been shown, by mass spectrometry analysis, to be highly upregulated in SLE MPs [12] , could be blocked and hidden on MP surfaces by aPLs/anti-b 2 GPI antibodies. This blockage is likely to disturb important scavenging mechanisms and eventually lead to accumulation of circulating cellular debris in aPL/anti-b 2 GPI-positive individuals. From a technical point of view, it is also likely that shielding of PS-b 2 GPI complexes by aPLs on MPs interferes with conventional PS-dependent MP detection.
Initially, we confirmed our previous observation that SLE patients, regardless of aPL status, have elevated numbers of total MPs as compared with healthy controls [10] . The results show all MPs regardless of their ability to express PS. The increased numbers of MPs observed in SLE patients most likely result from defective clearance together with enhanced cell activation and apoptosis, which are all mechanisms related to underlying SLE pathogenesis, as discussed elsewhere [10, 11, 16, 17] . Moreover, elevated numbers of endothelial and platelet MPs have previously also been demonstrated in APS patients [9, 18, 19] . In addition to elevated concentrations of MPs, SLE patients have high concentrations of mpICs. These mpICs are larger than MPs, as described recently, and could be more proinflammatory [10, 15, 20] . Our results demonstrate a high prevalence of IgGs in mpICs. These IgGs are most likely a mixture of several specificities, such as antinuclear antibodies, anti-annexin-V, anti-PS/ prothrombin (aPS/PT), and anti-b 2 GPI. Interestingly, the number of b 2 GPI-expressing MPs was depressed among SLE patients, and particularly low among aPL/anti-b 2 GPI-positive patients (Fig. 2) . b 2 GPI, which is an abundant plasma protein, promotes clearance of PS-expressing surfaces (cells or particles) from the circulation by binding with high affinity to anionic phospholipids, such as PS [21] [22] [23] . b 2 GPI in plasma is normally present as a circular protein; however, by binding to PS, it undergoes conformational changes and 'opens up' to a J shape, thus exposing antibody-binding sites [4] . As MPs expose PS on their surfaces they offer a binding site for circulating b 2 GPI, as shown previously with PS-coated vesicles or PS-exposing cell surfaces [24, 25] . Previous work from Nomura et al. demonstrated that b 2 GPI can bind directly to PMPs generated in vitro [26] . The results from our in vitro experiments confirm the findings of Nomura et al., and we also demonstrate that b 2 GPI preferentially binds to PS-expressing PMPs rather than to PSnegative PMPs, providing further evidence that b 2 GPI binds to MPs in the circulation. Sourindra et al. demonstrated that b 2 GPI-PS complexes on vesicles and apoptotic bodies are normally cleared by macrophages through uptake by LDL receptors [23] . Subsequent binding of anti-b 2 GPI antibodies to b 2 GPI-PS complexes on MP surfaces may interrupt this clearance and explain why aPL/anti-b 2 GPI-positive patients have the lowest concentration of b 2 GPI-positive MPs. Although further studies are needed, flow cytometric counting of b 2 GPIexpressing MPs, as described in this study, could be an alternative technique to identify aPL-positive patients. ) , a scavenger molecule, has a specific binding site for PS, and can bind to PS-exposing MPs and facilitate the clearance of MPs by binding b 2 GPI receptors (LDL receptors) on phagocytes. However, this clearance mechanism is inhibited in the presence of aPLs, as aPLs can bind and block b 2 GPI-PS expression on MPs. Therefore, the clearance mechanism is switched to alternative pathways such as Fcc-mediated antibody-dependent phagocytosis, subsequently also inducing a proinflammatory response. MPs are frequently identified on the basis of size and PS expression by labeling MPs with PS-binding lactadherin or annexin-V. In aPL-positive patients, lactadherin/annexin-V fail to bind to PS on many MPs, as PS is blocked by b 2 GPI-aPL-aPL/anti-b 2 -GPI complexes. These MPs will be recognized as PSnegative MPs and subsequently ignored in the data analysis, thus causing incomplete measurement of the 'total' MP concentration in the presence of aPLs. [Color figure can be viewed at wileyonlinelibrary.com]
We previously reported 7-10-fold higher numbers of MPs in SLE patients than in matched controls. Importantly, in SLE patients, but not in controls, the majority of MPs did not express PS [10] . By blocking PS expression on MPs and apoptotic bodies, aPLs may contribute to impaired PS-dependent or PS-b 2 GPI-dependent clearance of particles and cellular remnants [23, 27] . Other aPL subgroups, especially aPS/PT antibodies, could, in a similar fashion, block PS-mediated clearance [28] . It has been shown in immune mice that PS-exposing vesicles (multilaminar lipid vesicles) are cleared rapidly in the presence of anti-b 2 GPI antibodies. In addition, the authors showed that vesicles not exposing PS were cleared significantly more slowly than PS-exposing vesicles. [25] . The shielding of PS on MPs in SLE patients could explain why high numbers of unrecognized MPs remain in the circulation, where they can continuously expose endogenous antigens, including nuclear components, for the immune system and trigger autoimmune responses [17] . This sequence of events could also explain the observation that aPLs appear early in a subgroup of SLE patients, preceding the occurrence of antibodies against double-stranded DNA and the onset of SLE by several years [29] [30] [31] . Furthermore, in line with a recent review by Andreoli et al. [32] , PS-negative MPs decorated with anti-b 2 GPI and other PS-binding antibodies can form structures similar to immune complexes, which are likely to be cleared by Fcc receptors through antibody-mediated phagocytosis. The state of complement activation and systemic inflammation that is known to characterize patients with APS could also partly be explained by activation of these more inflammatory mechanisms, as outlined in Fig. 5 [21, 33] .
Healthy controls had higher levels of b 2 GPI-positive MPs than SLE patients. These results are in line with the known properties of b 2 GPI as an important scavenger molecule. We did not measure anti-b 2 GPI antibodies in healthy controls, but the presence of low-titer anti-b 2 GPI antibodies in the population has previously been reported, both in healthy children and in adults [34, 35] .
In contrast to what was found in the MP analysis, plasma levels of b 2 GPI did not differ between aPL/anti-b 2 GPI-positive and aPL/anti-b 2 GPI-negative patients. However, b 2 GPI levels were slightly higher in the control group than in aPL/ anti-b 2 GPI-positive patients. The discrepancy between the two assays could be related to sensitivity. We have previously shown that measurement of soluble proteins on MPs yields higher sensitivity, as the flow cytometer only measures proteins bound to particles, whereas ELISA measures both bound and soluble proteins [36] . A previous study by Vlachoyiannopoulos et al. showed that b 2 GPI levels in patients with APS were higher than those in SLE patients negative for aCLs [37] . The discrepancy could be explained by the fact that, in contrast to the citrated plasma used in the present study, they used serum, which contains numerous products of cell activation, including PS-positive MPs, that can interfere with b 2 GPI detection [38] . Another explanation could be differences in study populations and/or b 2 GPI conformation state.
MPs are frequently identified on the basis of PS expression (i.e. the 'classic definition'), by lactadherin or annexin-V binding. Our results, as well as previous data from Nomura et al. [26] , suggest that b 2 GPI binds to exposed PS-positive MPs, so the current methodology yields an incomplete analysis of the 'total' MP concentration in the presence of aPLs. This may explain why a large fraction of MPs are PS-negative in SLE and APS patients, as previously shown by us and others [9, 10] . In addition, we observed a high concentration of mpICs in SLE patients, indicating that MPs in SLE patients are covered with immunoglobulins, which could also interfere with the analysis. Consequently, a 'total' MP analysis in patients with SLE, APS and other autoimmune conditions should also include PS-negative MPs, as autoantibodies can bind to and block the surfaces of MPs [17, 39] .
To summarize, flow cytometric identification of MPs based on PS expression is not a reliable method in SLE and aPL-positive patients, owing to the presence of autoantibodies. SLE patients have high total MP concentrations and high concentrations of immunoglobulins on MPs. However, aPL/anti-b 2 GPI-positive patients have selectively decreased concentrations of b 2 GPI-positive MPs as compared with both aPL-negative SLE patients and healthy controls. Our results suggest that anti-b 2 GPI autoantibodies bind to b 2 GPI-PS complexes on the surfaces of MPs (Fig. 5) . Therefore, autoantibodies on MPs could impair scavenging and contribute to the accumulation of cellular debris, which subsequently triggers further autoimmune responses and also an inflammatory state through activation of alternative clearance pathways. We suggest that autoantibodies, in the manner outlined above, cause impaired MP clearance, and that delayed removal of MPs could be an important mechanism underlying and fueling autoimmunity in SLE and APS patients.
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